VA PITTSBURGH HEALTHCARE SYSTEM

Spectral Medical's Tigris Trial Nears Completion with Strong Enrollment

5 months ago

• Spectral Medical's Tigris trial, evaluating Polymyxin B Hemoperfusion (PMX) for endotoxemia and septic shock, has enrolled 146 patients, showing strong progress. • Enrollment in December 2024 saw improvement as intravenous fluid supply issues eased, contributing to a robust overall enrollment for the year. • The company projects full enrollment of 150 patients by the end of the first quarter of 2025, moving closer to potential FDA approval. • PMX has received Breakthrough Device Designation from the FDA and is already approved for use in Japan and Europe, marking a significant step in sepsis treatment.

Acupuncture Shows Promise in Alleviating Combat-Related PTSD Symptoms in Veterans

4 years ago

• A randomized, placebo-controlled trial is underway to evaluate the clinical and biological effects of verum acupuncture for combat-related PTSD in US Veterans. • The study compares verum acupuncture to sham acupuncture, assessing changes in PTSD symptom severity and psychophysiological responses. • Researchers aim to address limitations of previous acupuncture trials by including a sham control, biological outcomes, and monitoring protocol adherence. • Expected results will offer definitive insights into acupuncture's efficacy, potentially influencing PTSD treatment approaches within and beyond the VA system.